Latest Transformation News

MCS Security Services Limited reported a 63% revenue decline following the sale of its Security Business, yet improved its net loss and underlying EBITDA in FY25. The Traffic Business showed promising growth, while the company weighs capital management and potential divestments.

SOCO Corporation Ltd reported a 3.6% revenue increase to $21.29 million for FY25, reversing prior losses with a modest net profit after tax. Operational improvements and strategic hires underpin the company’s renewed momentum.

Spacetalk Ltd reported a transformative FY25 with a 25% increase in annual recurring revenue and a significant narrowing of losses, underpinned by strong subscriber growth and a strategic debt restructuring.

Spacetalk Limited reported a 12.2% revenue increase to $19.6 million in FY25, driven by recurring mobile subscriptions and device sales, while reducing its net loss by 27.1%. The company secured $3 million in capital post-year-end to support growth amid ongoing going concern uncertainties.

Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.

Resonance Health Limited reported a 29% revenue increase to $11.07 million for FY25 but posted a net loss of $1.73 million, reflecting strategic investments and expansion in clinical trial services.

Maggie Beer Holdings Ltd reports a transformative FY25 marked by strategic restructuring, significant cost savings, and a 3.7% sales increase excluding Paris Creek Farms. Despite EBITDA pressures from non-recurring investments, the company is positioning for sustainable profitability and growth in FY26.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

Immuron Ltd reported a robust 49% increase in FY25 global sales, driven by strong Travelan® growth, while gearing up for a ProIBS launch and pivotal FDA meetings in 2025-26.

Gale Pacific’s FY25 results reveal resilience amid US market challenges, with growth in Australia and the Middle East offsetting tariff impacts and prompting a major US operating restructure.

Finexia Financial Group's shares have been suspended from trading pending a significant announcement related to media speculation and a potential material acquisition.